Literature DB >> 18024084

Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors.

Masao Imaizumi1, Emmanuelle Briard, Sami S Zoghbi, Jonathan P Gourley, Jinsoo Hong, Yota Fujimura, Victor W Pike, Robert B Innis, Masahiro Fujita.   

Abstract

OBJECTIVES: Peripheral benzodiazepine receptors (PBRs) are upregulated on activated microglia and are thereby biomarkers of neuroinflammation. We developed a PET ligand with an aryloxyanilide structure, [O-methyl-(11)C]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine ([(11)C]PBR28), to image PBRs. The objectives of the current study were to evaluate kinetics of brain uptake, and the influence of the peripheral binding on the arterial input function in rhesus monkey.
METHODS: Brain (baseline: n=6, blocking: n=1) and whole-body PET imaging (baseline: n=3, blocking: n=1) of [(11)C]PBR28 were performed with the measurement of radiometabolite-corrected arterial input function in all brain and two whole body scans.
RESULTS: Saturating doses of nonradioactive PBR ligands markedly increased [(11)C]PBR28 in plasma (approximately 400% increase) and brain (approximately 200%) at 2 min by displacing radioligand from PBRs in peripheral organs. Brain uptake of radioactivity peaked in baseline scans at approximately 40 min after injection of [(11)C]PBR28 and was high (approximately 300% standardized uptake value). The images showed no receptor-free region that could be used for reference tissue analysis. Thus, quantitation of receptor density required measurement of parent radioligand in arterial plasma. Nondisplaceable uptake was estimated from the blocked scans and was only approximately 5% of total distribution volume measured under baseline conditions. Distribution volume of [(11)C]PBR28 was stably determined within 110 min of scanning.
CONCLUSIONS: Regional brain uptake of [(11)C]PBR28 in monkey could be quantified as a value proportional to the density of receptors--namely, as equilibrium distribution volume. [(11)C]PBR28 had high levels of specific binding in brain and should provide a sensitive measure of changes in PBRs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024084      PMCID: PMC2275117          DOI: 10.1016/j.neuroimage.2007.09.063

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  25 in total

1.  High densities of benzodiazepine receptors in human cortical areas.

Authors:  C Braestrup; R Albrechtsen; R F Squires
Journal:  Nature       Date:  1977-10-20       Impact factor: 49.962

2.  The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane.

Authors:  R R Anholt; P L Pedersen; E B De Souza; S H Snyder
Journal:  J Biol Chem       Date:  1986-01-15       Impact factor: 5.157

3.  Peripheral-type benzodiazepine receptors in the central nervous system: localization to olfactory nerves.

Authors:  R R Anholt; K M Murphy; G E Mack; S H Snyder
Journal:  J Neurosci       Date:  1984-02       Impact factor: 6.167

4.  Labelling of "peripheral-type" benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization.

Authors:  J Benavides; D Quarteronet; F Imbault; C Malgouris; A Uzan; C Renault; M C Dubroeucq; C Gueremy; G Le Fur
Journal:  J Neurochem       Date:  1983-12       Impact factor: 5.372

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats.

Authors:  R R Anholt; E B De Souza; M L Oster-Granite; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1985-05       Impact factor: 4.030

7.  Evidence for species differences in 'peripheral' benzodiazepine receptors: an autoradiographic study.

Authors:  U Cymerman; A Pazos; J M Palacios
Journal:  Neurosci Lett       Date:  1986-05-15       Impact factor: 3.046

8.  PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report.

Authors:  S Pappata; P Cornu; Y Samson; C Prenant; J Benavides; B Scatton; C Crouzel; J J Hauw; A Syrota
Journal:  J Nucl Med       Date:  1991-08       Impact factor: 10.057

9.  Lung as reservoir for antidepressants in pharmacokinetic drug interactions.

Authors:  T Suhara; Y Sudo; K Yoshida; Y Okubo; H Fukuda; T Obata; K Yoshikawa; K Suzuki; Y Sasaki
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

10.  Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET.

Authors:  R A Hawkins; M E Phelps; S C Huang
Journal:  J Cereb Blood Flow Metab       Date:  1986-04       Impact factor: 6.200

View more
  50 in total

1.  Endotoxin-induced systemic inflammation activates microglia: [¹¹C]PBR28 positron emission tomography in nonhuman primates.

Authors:  Jonas Hannestad; Jean-Dominique Gallezot; Thomas Schafbauer; Keunpoong Lim; Tracy Kloczynski; Evan D Morris; Richard E Carson; Yu-Shin Ding; Kelly P Cosgrove
Journal:  Neuroimage       Date:  2012-07-06       Impact factor: 6.556

2.  [11C]PBR28 PET imaging is sensitive to neuroinflammation in the aged rat.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Nathan V Lee; Qing Miao; Mike Adam; Christine Takhar; Edwin Mak; Michael Schulzer; Matthew J Farrer; Vesna Sossi
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-01       Impact factor: 6.200

3.  In vivo binding of protoporphyrin IX to rat translocator protein imaged with positron emission tomography.

Authors:  Harushige Ozaki; Sami S Zoghbi; Jinsoo Hong; Ajay Verma; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  Synapse       Date:  2010-08       Impact factor: 2.562

Review 4.  Imaging of atherosclerosis.

Authors:  D R J Owen; A C Lindsay; R P Choudhury; Z A Fayad
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 5.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

Review 6.  Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies.

Authors:  Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis
Journal:  Pharmacol Biochem Behav       Date:  2019-01-26       Impact factor: 3.533

7.  [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain.

Authors:  S Lavisse; K Inoue; C Jan; M A Peyronneau; F Petit; S Goutal; J Dauguet; M Guillermier; F Dollé; L Rbah-Vidal; N Van Camp; R Aron-Badin; P Remy; P Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-09       Impact factor: 9.236

8.  Biodistribution and radiation dosimetry in humans of a new PET ligand, (18)F-PBR06, to image translocator protein (18 kDa).

Authors:  Yota Fujimura; Yasuyuki Kimura; Fabrice G Siméon; Leah P Dickstein; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

Review 9.  Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers.

Authors:  Fabien Chauveau; Hervé Boutin; Nadja Van Camp; Frédéric Dollé; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-01       Impact factor: 9.236

10.  Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

Authors:  Anna L Bartels; Klaus L Leenders
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.